35.0 D-
CJC-1295
Also known as: CJC1295, DAC:GRF
Emerging Research Category 2 Restricted
Research Evidence 20.0/100
Safety Profile 50.0/100
1 Clinical Trial
PHASE2: 1
- A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity PHASE2 TERMINATED ConjuChem
11 Research Papers
- Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS. Drug Test Anal unknown
- The study of doping market: How to produce intelligence from Internet forums. Forensic Sci Int unknown
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse Review
- Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Rev Proteomics unknown
- Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor. Talanta unknown
Showing 5 of 11 papers by citation count.
FDA Data
Not FDA-Approved
CJC-1295 has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.
This peptide is classified as FDA Category 2 — it is prohibited from use in compounding pharmacies effective 2024. Obtaining it requires unregulated sources.
Frequently Asked Questions
Is CJC-1295 FDA approved?
No, CJC-1295 is not FDA approved. It is classified as FDA Category 2 and is banned from compounding pharmacies.
How many clinical trials has CJC-1295 been studied in?
CJC-1295 has been studied in 1 registered clinical trial. CheckPeptides tracks phase, status, and sponsor data for each trial.
What is the trust score for CJC-1295?
CJC-1295 has a CheckPeptides trust score of 35.0/100 (grade: D-). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 7, 2026
Quick Facts
- Classification
- GHRH analogue
- Molecular Weight
- 3647.2 Da
- PubChem
- CID 91971820 ↗
- Regulatory Status
- N/A
Score Breakdown
Research Evidence 20.0/100
Safety Profile 50.0/100
Evidence Summary
- Clinical Trials
- 1
- Research Papers
- 11
- Trust Score
- 35.0/100
- Grade
- D-